Scientific Sessions
Scientific Sessions
  • Program
  • #AHA24
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Photo Gallery
  • Journeys
Topics
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Photo Gallery
  • Journeys
Resources
  • Program
  • #AHA24
User Tools
  • Privacy Policy
  • Terms & Conditions
  • Accessibility Statement
Twitter X icon Facebook iconInstagram iconYouTube iconPinterest iconLinkedIn icon
Nov 18th, 2024

AHA CEO: Driving breakthroughs

AHA CEO describes how to continue to deliver on the AHA mission during its second century.


Nancy Brown headshot
Brown

Nancy Brown, AHA CEO, welcomed everyone to yesterday’s Presidential Session with a message 100 years in the making.

"Since our founding in 1924, deaths from cardiovascular diseases have been cut in half. And yet, there are still so many lives to be saved,” she said. “By driving breakthroughs in science, policy and care, together, we can continue to deliver on this mission in powerful new ways during our second century.”

Brown underscored last year’s AHA success in defining cardiovascular-kidney-metabolic syndrome, saying that, over the next four years, the association will engage an initial 150 hospitals and sites to advance guidelines for CKM care, with plans to expand to the nearly 2,900 Get With The Guidelines hospitals nationwide, which will impact 89 million patients in the U.S. who are at risk for, or living with, CKM syndrome.

Brown also pointed to the game-changing impact of GLP-1 agonists for diabetes, cardiovascular outcomes and weight management, pointing to the AHA’s Healthy Living BEYOND Weight Study that will examine individuals living with overweight or obesity, to improve understanding of the causes and treatments of the conditions.

Interesting Stories
CME Gameshow Style Sympo: Navigating New Paradigms in Thrombosis Management
Sponsored by Medscape
CME Gameshow Style Sympo: Navigating New Paradigms in Thrombosis Management
Lp(a) and Peripheral Artery Disease Toolkit
Sponsored by Kaneka Corporation
Lp(a) and Peripheral Artery Disease Toolkit
Screening for Kidney Disease to Reduce CVD Risk
Sponsored by Bayer
Screening for Kidney Disease to Reduce CVD Risk
Unmet Needs in Hypertension Toolkit
Sponsored by Medtronic
Unmet Needs in Hypertension Toolkit
More Content
Health Tech winners
AHA24
AI medical company wins global health tech competition at #AHA24
Nov 20th, 2024
241116 American Heart Association Keynote 0080
AHA24
LBS 08: Advances in lipid therapeutics
Nov 20th, 2024
Crowd shot
AHA24
LBS 07: New approaches to managing AFib
Nov 20th, 2024
Stage shot
AHA24
LBS 06: Medical therapy for heart failure
Nov 20th, 2024
Stage shot
AHA24
LBS 05: Innovation in prevention
Nov 20th, 2024
French Quarter balcony shot
AHA24
Save the date for #AHA25 in New Orleans
Nov 20th, 2024
Asgar headshot
AHA24
Managing patients with symptomatic mitral or tricuspid regurgitation
Nov 18th, 2024
Shot of speakers
AHA24
Environmental crises call for more CV research
Nov 18th, 2024
Churchwell
AHA24
Wake-up call: Heeding global risk factors
Nov 18th, 2024
Aha24 Nejm Web Image
AHA24
Streamlining the pathway to publish cardiovascular research
Nov 18th, 2024
Casadei headshot
AHA24
Dissecting the complex relationship between atrial cardiomyopathy and stroke
Nov 18th, 2024
Stage shot
AHA24
LBS 04: Coronary and valvular heart disease
Nov 18th, 2024